Sarepta Therapeutics (SRPT) Equity Ratio (2010 - 2026)

Sarepta Therapeutics' Equity Ratio history runs 17 years deep, the most recent figure standing at 0.47 for Q1 2026.

• In Q1 2026, Equity Ratio rose 43.58% year-over-year to 0.47; the TTM figure through Mar 2026 stood at 0.47 (up 43.58% YoY), while the FY2025 annual figure was 0.34, down 11.67% from the prior year.
• Equity Ratio was 0.47 for Q1 2026 at Sarepta Therapeutics, up from 0.34 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.47 in Q1 2026 to a low of 0.12 in Q4 2022.
• Historically, Equity Ratio has averaged 0.29 across 5 years, with a median of 0.3 in 2024.
• The sharpest annual moves came in 2022 and 2023: Equity Ratio slumped 58.26% in 2022, then jumped 113.92% in 2023.
• A 5-year view of Equity Ratio shows it stood at 0.12 in 2022, then jumped by 113.92% to 0.26 in 2023, then jumped by 46.44% to 0.39 in 2024, then fell by 11.67% to 0.34 in 2025, then soared by 39.04% to 0.47 in 2026.
• The last three Equity Ratio figures came in at 0.47 (Q1 2026), 0.34 (Q4 2025), and 0.38 (Q3 2025), per Business Quant data.